Bayer eyes break-up, management cuts on disappointing Q3 results
Bayer eyes break-up, management cuts on disappointing Q3 results
Bayer eyes break-up, management cuts on disappointing Q3 results
Published: Nov 08, 2023
By Kate Goodwin
BioSpace
Bayer is looking to shake things up with some major company changes after reporting “not acceptable” cash flow for the third quarter on Wednesday.
“We’re not happy with this year’s performance,” CEO Bill Anderson said in a statement accompanying third-quarter results that were down against the previous year, while emphasizing a need for redesigning the company to focus only on what’s essential for its mission of “health for all, hunger for none.”
As part of a significant, unspecified reduction in its workforce, Bayer will remove “several layers” of management, according to Wednesday’s announcement. The goal is to shift the majority of decision-making from the managers to the people doing the work, Anderson said, adding that 12 layers of management between him and the company’s customers were “simply too much.”
The company reported nearly 50 billion euros, or $53.3 billion, in revenue with what Anderson called “zero cash flow.” Third-quarter sales of Bayer’s pharmaceuticals were level compared to last year at $4.8 billion. Quarterly core earnings per share decreased by 66.4% year-over-year. The company noted near-double sales growth for its cancer drug Nubeqa, with greater than double percentage growth for its chronic kidney disease treatment Kerendia.
Bayer confirmed its updated 2023 guidance and will rely on a strong fourth quarter to get the company there. However, a “soft growth outlook and continued challenges” are anticipated for 2024.
As part of its redesign, Bayer is reviewing its structural options, considering a separation of either its consumer health or crop science businesses. At this point they’ve ruled out splitting the company into three businesses at once but may still split all three in a two-step process.
“We are not wedded to one structure,” Anderson said. “We will pursue the best course to ensure maximum value creation.”
Anderson came to Bayer from Roche in June 2023, after his predecessor faced heavy criticism for not dealing with a continued share price slump. The lawsuits over the company’s Roundup weed killer are a heavy weight on the stock, which is down around 13% year-to-date.
Separating its consumer health arm would certainly follow an industry trend. Last month, Sanofi announced plans for a spin-off, abandoning its operating profit margin growth goal for 2025. Earlier this year, Johnson & Johnson launched Kenvue for its consumer health business.
Further details on Bayer’s structural reorganization are to be announced in March 2024 at the company’s Capital Markets Day and annual report publication.
Kate Goodwin is a freelance life science writer based in Des Moines, Iowa. She can be reached at [email protected] and on LinkedIn.
Source: BioSpace
This site uses cookies. By continuing to browse the site, you are agreeing to our use of cookies.
Accept settingsHide notification onlySettingsWe may request cookies to be set on your device. We use cookies to let us know when you visit our websites, how you interact with us, to enrich your user experience, and to customize your relationship with our website.
Click on the different category headings to find out more. You can also change some of your preferences. Note that blocking some types of cookies may impact your experience on our websites and the services we are able to offer.
These cookies are strictly necessary to provide you with services available through our website and to use some of its features.
Because these cookies are strictly necessary to deliver the website, refusing them will have impact how our site functions. You always can block or delete cookies by changing your browser settings and force blocking all cookies on this website. But this will always prompt you to accept/refuse cookies when revisiting our site.
We fully respect if you want to refuse cookies but to avoid asking you again and again kindly allow us to store a cookie for that. You are free to opt out any time or opt in for other cookies to get a better experience. If you refuse cookies we will remove all set cookies in our domain.
We provide you with a list of stored cookies on your computer in our domain so you can check what we stored. Due to security reasons we are not able to show or modify cookies from other domains. You can check these in your browser security settings.
We also use different external services like Google Webfonts, Google Maps, and external Video providers. Since these providers may collect personal data like your IP address we allow you to block them here. Please be aware that this might heavily reduce the functionality and appearance of our site. Changes will take effect once you reload the page.
Google Webfont Settings:
Google Map Settings:
Google reCaptcha Settings:
Vimeo and Youtube video embeds: